Is Polivy Approved for DLBCL?
Yes, Polivy (polatuzumab vedotin-piiq) is FDA-approved to treat diffuse large B-cell lymphoma (DLBCL) in adults with relapsed or refractory disease after at least two prior therapies. It is used in combination with bendamustine and rituximab.[1]
How Is Polivy Used in DLBCL Treatment?
Polivy targets CD79b on B-cells and delivers a toxin to kill cancer cells. The standard regimen is Polivy 1.8 mg/kg IV plus bendamustine 90 mg/m² and rituximab 375 mg/m², given every 21 days for up to eight cycles. Approval came in June 2019 based on the GO29365 trial, where the combo achieved 40% complete response rate versus 18% with bendamustine-rituximab alone.[1][2]
What About Frontline DLBCL Treatment?
Polivy gained expanded approval in 2023 for previously untreated DLBCL, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP). The POLARIX trial showed it improved progression-free survival (76% vs 70% at 2 years) without increasing overall toxicity.[1][3]
Who Cannot Use Polivy for DLBCL?
It is not approved as monotherapy or for first-line use without the specified combos. Patients with active infections, severe liver/kidney issues, or hypersensitivity to components should avoid it. Use caution in those with neuropathy or prior anthracycline exposure.[1]
Common Side Effects in DLBCL Patients
Frequent issues include neutropenia (42%), thrombocytopenia (27%), anemia (22%), fatigue, diarrhea, and peripheral neuropathy (up to 40% with some grade 3 cases). Infusion reactions occur in 7-10%; monitor for tumor lysis syndrome.[1][2]
Upcoming Patent Details for Polivy
Polivy's key composition-of-matter patent (US 8,153,768) expires in 2028, with formulation patents extending to 2031. No biosimilars are approved yet; challenges from Amgen and others are pending.[4]
[1]: FDA Prescribing Information for Polivy
[2]: NEJM: Polatuzumab Vedotin in Relapsed/Refractory DLBCL
[3]: Lancet: POLARIX Trial Results
[4]: DrugPatentWatch: Polivy Patents